McNeil St. Joseph “Aspirin Therapy” Claim Needs Refining, NAD Says
This article was originally published in The Tan Sheet
Executive Summary
McNeil Consumer & Specialty Pharmaceuticals should more narrowly target future advertising claims for St. Joseph Adult Low-Strength Aspirin "to avoid the risk of inaccurately communicating that 81 mg is the appropriate and recommended dosage for all types of 'aspirin therapy,'" the National Advertising Division says
You may also be interested in...
McNeil compliance with NAD
Ad watchdog "considered it incredibly unfortunate" that a St. Joseph aspirin TV commercial "continued to air without modification for months after" NAD deemed the ad misleading, according to recent Case Reports. In February, CBBB division concluded McNeil should modify ad claims for St. Joseph to avoid inaccurately communicating 81 mg is the appropriate, recommended dosage for aspirin therapy (1"The Tan Sheet" March 25, 2002, p. 6). In response to NAD compliance proceeding, McNeil said original ad aired through May while revisions were planned and instituted. The case, brought by Bayer, has since moved to federal court (2"The Tan Sheet" April 29, 2002, p. 14)...
McNeil compliance with NAD
Ad watchdog "considered it incredibly unfortunate" that a St. Joseph aspirin TV commercial "continued to air without modification for months after" NAD deemed the ad misleading, according to recent Case Reports. In February, CBBB division concluded McNeil should modify ad claims for St. Joseph to avoid inaccurately communicating 81 mg is the appropriate, recommended dosage for aspirin therapy (1"The Tan Sheet" March 25, 2002, p. 6). In response to NAD compliance proceeding, McNeil said original ad aired through May while revisions were planned and instituted. The case, brought by Bayer, has since moved to federal court (2"The Tan Sheet" April 29, 2002, p. 14)...
McNeil compliance with NAD
Ad watchdog "considered it incredibly unfortunate" that a St. Joseph aspirin TV commercial "continued to air without modification for months after" NAD deemed the ad misleading, according to recent Case Reports. In February, CBBB division concluded McNeil should modify ad claims for St. Joseph to avoid inaccurately communicating 81 mg is the appropriate, recommended dosage for aspirin therapy (1"The Tan Sheet" March 25, 2002, p. 6). In response to NAD compliance proceeding, McNeil said original ad aired through May while revisions were planned and instituted. The case, brought by Bayer, has since moved to federal court (2"The Tan Sheet" April 29, 2002, p. 14)...